Wedbush analyst David Nierengarten reiterated an Outperform rating and $8.00 price target on Sutro Biopharma (NASDAQ: STRO)The analyst comments "STRO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE